Who are BT524's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BT595, BT524 (Part II), BT524 (Part I).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bt524.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

BT524 — Competitive Intelligence Brief

BT524 (BT524) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (anti-TFPI). Area: Hematology.

phase 3 Monoclonal antibody (anti-TFPI) Tissue Factor Pathway Inhibitor (TFPI) Hematology Biologic Live · refreshed every 30 min

Target snapshot

BT524 (BT524) — Biotest. BT524 is a human monoclonal antibody that binds to and neutralizes tissue factor pathway inhibitor (TFPI) to enhance thrombin generation and hemostasis.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BT524 TARGET	BT524	Biotest	phase 3	Monoclonal antibody (anti-TFPI)	Tissue Factor Pathway Inhibitor (TFPI)
BT595	BT595	Biotest	phase 3	Monoclonal antibody (anti-TFPI)	Tissue Factor Pathway Inhibitor (TFPI)
BT524 (Part II)	BT524 (Part II)	Biotest	phase 3	Monoclonal antibody (anti-TFPI)	Tissue Factor Pathway Inhibitor (TFPI)
BT524 (Part I)	BT524 (Part I)	Biotest	phase 3	Monoclonal antibody (anti-TFPI)	Tissue Factor Pathway Inhibitor (TFPI)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (anti-TFPI) class)

Biotest · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BT524 — Competitive Intelligence Brief. https://druglandscape.com/ci/bt524. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab